TY - JOUR
T1 - Non-specific effects of the inactivated influenza vaccine. A test-negative study
T2 - The inactivated influenza vaccine and SARS-CoV-2 infections
AU - Sellies, Anne Jasmijn
AU - Knol, Mirjam J.
AU - de Melker, Hester E.
AU - Bruijning-Verhagen, Patricia C.J.L.
AU - de Boer, Annemarijn R.
N1 - Publisher Copyright:
© 2024 Elsevier India Pvt Ltd.
PY - 2024/5/31
Y1 - 2024/5/31
N2 - Background: Previous research suggested that the inactivated influenza vaccine (IIV) may protect against SARS-CoV-2 infection or a severe course of COVID-19. These findings were however based on cohort studies, that are prone to confounding by indication. We examined the association between IIV and SARS-Cov-2 infection in a Dutch population using a test-negative design. Methods: This test-negative case-control study was conducted in adults (≥60) who tested because of COVID-19 like symptoms at community SARS-CoV-2 testing locations in the Netherlands during the period of November 8th 2021-March 11th 2022. Information on receipt of IIV in October-November 2021 was routinely collected at each visit. Logistic regression was used to calculate unadjusted, partially (sex, age, education level) and fully adjusted (COVID-19 vaccination, IIV 2020) odds ratios (ORs) for receipt of IIV in SARS-CoV-2 positive versus negative subjects. Differential effects on SARS-CoV-2 risk by time since IIV were investigated by including an interaction term for calendar time: November 2021-January 2022 vs February-March 2022. Results: In total, 1,832 participants were included in the main analysis, of whom 336 (18.3 %) had a positive SARS-CoV-2 test. No significant association between IIV and SARS-CoV-2 infection was found; fully adjusted OR of 1.07 (95 % CI: 0.78–1.49). The interaction term for time periods was not significant (1.04 [95 % CI: 0.51–2.15], p = 0.91). Results were robust in sensitivity analyses. Conclusions: While earlier observational studies suggested a protective non-specific effect of IIV and SARS-CoV-2 infections, this smaller, but well controlled test-negative design study does not suggest an effect, either positive or negative. Larger test-negative design studies, or alternative designs such as the self-controlled case series design are needed to confirm these findings and provide more definite answers on the topic.
AB - Background: Previous research suggested that the inactivated influenza vaccine (IIV) may protect against SARS-CoV-2 infection or a severe course of COVID-19. These findings were however based on cohort studies, that are prone to confounding by indication. We examined the association between IIV and SARS-Cov-2 infection in a Dutch population using a test-negative design. Methods: This test-negative case-control study was conducted in adults (≥60) who tested because of COVID-19 like symptoms at community SARS-CoV-2 testing locations in the Netherlands during the period of November 8th 2021-March 11th 2022. Information on receipt of IIV in October-November 2021 was routinely collected at each visit. Logistic regression was used to calculate unadjusted, partially (sex, age, education level) and fully adjusted (COVID-19 vaccination, IIV 2020) odds ratios (ORs) for receipt of IIV in SARS-CoV-2 positive versus negative subjects. Differential effects on SARS-CoV-2 risk by time since IIV were investigated by including an interaction term for calendar time: November 2021-January 2022 vs February-March 2022. Results: In total, 1,832 participants were included in the main analysis, of whom 336 (18.3 %) had a positive SARS-CoV-2 test. No significant association between IIV and SARS-CoV-2 infection was found; fully adjusted OR of 1.07 (95 % CI: 0.78–1.49). The interaction term for time periods was not significant (1.04 [95 % CI: 0.51–2.15], p = 0.91). Results were robust in sensitivity analyses. Conclusions: While earlier observational studies suggested a protective non-specific effect of IIV and SARS-CoV-2 infections, this smaller, but well controlled test-negative design study does not suggest an effect, either positive or negative. Larger test-negative design studies, or alternative designs such as the self-controlled case series design are needed to confirm these findings and provide more definite answers on the topic.
KW - Influenza vaccination
KW - Non-specific effects
KW - Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection
KW - Test-negative design
UR - http://www.scopus.com/inward/record.url?scp=85190987044&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2024.04.044
DO - 10.1016/j.vaccine.2024.04.044
M3 - Article
AN - SCOPUS:85190987044
SN - 0264-410X
VL - 42
SP - 3455
EP - 3460
JO - Vaccine
JF - Vaccine
IS - 15
ER -